Previous 10 | Next 10 |
Puma Biotechnology (NYSE: PBYI ) +30% on Q4 earnings . More news on: Puma Biotechnology, Inc., Funko, Inc., The Gap, Inc., Stocks on the move, Read more ...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending Sanofi's (NASDAQ: SNY ) Zynquista (sotagliflozin) as an adjunct to insulin to improve glycemic control in overweight type 1 diabetics (Body Mass Index ≥ 27 kg/m2) who have failed to achie...
PARIS and THE WOODLANDS, Texas, March 01, 2019 (GLOBE NEWSWIRE) -- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Marketing Authorization of Zynquista™* (sotagliflozin), developed by Sanofi and Lexico...
THE WOODLANDS, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from two posters highlighting XERMELO ® (telotristat ethyl) will be presented at the upcoming 16 th Annual European Neuroendocrine Tumor Society ...
NEW YORK, NY / ACCESSWIRE / February 15, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company")(NASDAQ: LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securi...
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of WPX Energy, Inc. (NYSE:WPX), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)...
SAN DIEGO, CA / ACCESSWIRE / February 4, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX). Investors, who purchased shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), have certain...
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Knight-Swift Transportation Holdings Inc. (NYSE:KNX), Alteryx, Inc. (NYSE...
NEW YORK, NY / ACCESSWIRE / January 7, 2019 / Traders News Source, aleading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive report on Lexicon Pharmaceuticals, Inc.(NASDAQ: LXRX ), a biopharmaceutical company tha...
(Source: Evil Speculator) Anyone thinking 2018 investing hasn’t been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...